Evidence map›Paper›PMID 30207092›Full record

ArticleJournal of gynecologic oncology2018

Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.

Min Hyun Baek, Dae Yeon Kim, Seon Ok Kim, Ye Jee Kim, Young Han Park

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Critically ill patients with cancer: A clinical perspective.World journal of clinical oncology · 2020
    Review
  18. Review
  19. Article
  20. Beyond the tumour microenvironment.International journal of cancer · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Min Hyun BaekDepartment of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea.ORCID https://orcid.org/0000-0003-0423-9038
Dae Yeon KimDepartment of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. kdyog@amc.seoul.kr.ORCID https://orcid.org/0000-0002-8068-3475
Seon Ok KimDepartment of Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0001-9010-5460
Ye Jee KimDepartment of Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Young Han ParkDepartment of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea.
Ulsan College · KRHallym University Sacred Heart Hospital · KR

Funding

Hallym University HURF-2016-06
6 · The paper itself

Abstract

objectiveThe impact of beta blockers (BBs) on survival outcomes in ovarian cancer was investigated.

methodsBy using Korean National Health Insurance Service Data, Cox proportional hazards regression was performed to analyze hazard ratios (HRs) with 95% confidence intervals (CIs) adjusting for confounding factors.

resultsAmong 866 eligible patients, 206 (23.8%) were BB users and 660 (76.2%) were non-users. Among the 206 BB users, 151 (73.3%) were non-selective beta blocker (NSBB) users and 105 (51.0%) were selective beta blocker (SBB) users. BB use in patients aged ≥60 years, longer duration use (≥1 year), in patients with Charlson Comorbidity Index (CCI) ≥3, and in cardiovascular disease including hypertension was associated with better survival outcome. These findings were observed in both NSBB and SBB. When duration of medication was analyzed based on number of days, NSBB (≥180 days) was associated with improved overall survival (OS) with a relatively shorter period of use compared to SBB (≥720 days). In multivariate Cox proportional hazards model, longer duration of BB medication (≥1 year) was an independent favorable prognostic factor for both OS and disease-specific survival in ovarian cancer patients.

conclusionIn our nationwide population-based cohort study, BB use was associated with better survival outcomes in ovarian cancer in cases of long term duration of use, in older patients, and in cardiovascular and/or other underlying disease (CCI ≥3).

Indexed as

Adrenergic beta-AntagonistsAdultAge FactorsBevacizumabCardiovascular DiseasesCohort StudiesFemaleHumansHypertensionMiddle AgedOvarian NeoplasmsProportional Hazards ModelsRepublic of KoreaSurvival RateTime FactorsAdrenergic beta-AntagonistsBevacizumabAdrenergic beta-AntagonistsOvarian NeoplasmsSurvivalTreatment Outcome

Identifiers

PMID30207092
PMCPMC6189440
OpenAlexW2884101600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.